Proposal on the funding of infliximab, rituximab and tocilizumab

PHARMAC

6 September 2018 - PHARMAC is proposing to change how three hospital medicines are managed within the Pharmaceutical Schedule.

The medicines are:

  • Infliximab (Remicade)
  • Rituximab (Mabthera)
  • Tocilizumab (Actemra)

These medicines are currently listed in Section H with restrictions applying to their use in DHB hospitals. This change would result in these medicines also being listed in Section B of the Pharmaceutical Schedule from 1 February 2019, with a two-month phase-in period, meaning that the changes would be fully implemented from 1 April 2019.

Read PHARMAC consultation

Michael Wonder

Posted by:

Michael Wonder